{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"PFS is defined as the time from date of study treatment to the first documented PD based on RECIST v.1.1, or death due to any cause, whichever occurs first. PD: at least a 20% increase in the sum of diameters of target lesions.","groups":[{"description":"Participants were planned to receive TAK-500 at recommended doses based on dose escalation cohorts. No participants were enrolled in the expansion phase due to early termination of the study before initiating this phase.","id":"OG000","title":"Dose Expansion: TAK-500"}],"populationDescription":"Due to early study termination, Dose Expansion Phase was not initiated and hence, no data was collected for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Up to approximately 32.8 months","title":"Dose Expansion: Progression Free Survival (PFS)","type":"SECONDARY"}